國家衛生研究院 NHRI:
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 910054      在线人数 : 800
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版
    邻近类别
    圖書 [1/1]
    期刊論文 [327/330]

    类别统计

    近3年内发表的文件:16(8.94%)
    含全文笔数:115(64.25%)

    文件下载次数统计
    下载大于0次:115(100.00%)
    下载大于100次:112(97.39%)
    全文下载总次数:39325(22.06%)

    最后更新时间: 2024-12-01 10:33


    上传排行

    数据加载中.....

    下载排行

    数据加载中.....

    RSS Feed RSS Feed
    跳至:
    或输入年份:
    由新到旧排序 由最旧的开始

    显示项目1-50 / 179. (共4页)
    1 2 3 4 > >>
    每页显示[10|25|50]项目

    日期题名關聯
    2023-11 Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
    2023-11 Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis Annals of Oncology. 2023 Nov;34(Suppl. 4):S1536-S1537.
    2023-10 Risk of type 2 diabetes mellitus and hyperlipidemia in patients with chronic myeloid leukemia initiating tyrosine kinase inhibitors: A nationwide cohort study Pharmacoepidemiology and Drug Safety. 2023 Oct;32(Suppl. S1):575.
    2023-06 Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors Journal of Clinical Oncology. 2023 Jun;41(16, Suppl.):Meeting Abstract 3148.
    2022-11 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462-S1463.
    2022-10 Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
    2022-09 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) Annals of Oncology. 2022 Sep;33(7):S565-S566.
    2022-07 Toward collaboration among cancer trials groups in Asia: TCOG perspective Annals of Oncology. 2022 Jul;33(Suppl. 6):S449.
    2022-07 Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
    2022-07 A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
    2022-07 Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
    2022-06 Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4009.
    2022-06 Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4120.
    2022-02-01 A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):378.
    2022-02-01 A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):550.
    2022-02 Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors Journal of Clinical Oncology. 2022 Feb;40(4, Suppl.):660.
    2021-09 INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC) Annals of Oncology. 2021 Sep;32(Suppl. 5):S1074.
    2021-09 A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer Annals of Oncology. 2021 Sep;32(Suppl. 5):S377.
    2021-09 Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements Oncology Research and Treatment. 2021 Sep;44(Suppl. 2):222.
    2021-07 Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements Cancer Research. 2021 Jul;81(13, Suppl.):Abstract number CT010.
    2021-05 Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 4090.
    2021-05 TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma Journal of Clinical Oncology. 2021 May;39(15, Suppl.):4143.
    2021-05 A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025.
    2020-09 Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer Annals of Oncology. 2020 Sep;31(Suppl. 4):S268-S269.
    2020-09 Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study Annals of Oncology. 2020 Sep;31(Suppl. 4):S1192.
    2020-05 Establishing the common oncology data model for the national biobank consortium of Taiwan Journal of Clinical Oncology. 2020 May;38(15, Suppl.):Meeting Abstract e19283.
    2020-05 EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435) Journal of Clinical Oncology. 2020 May;38(15, Suppl.):Abstract number TPS4669.
    2020-02 Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study Journal of Clinical Oncology. 2020 Feb;38(4):Meeting Abstract 477.
    2020-02 A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data Journal of Clinical Oncology. 2020 Feb;38(4):Meeting Abstract 383.
    2019-10 Chemo-radiotherapy in adjuvant therapy of curatively resected pancreatic cancer: Lesions from TCOG T3207 study Annals of Oncology. 2019 Oct;30(Suppl. 6):75.
    2019-10 Interpretation the results of adjuvant chemotherapy in curatively resected pancreatic cancer Annals of Oncology. 2019 Oct;30(Suppl. 6):vi 78.
    2019-10 Randomised phase 3 study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) - Integrate II Annals of Oncology. 2019 Oct;30(Suppl. 6):137.
    2019-10 A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 Annals of Oncology. 2019 Oct;30(Suppl. 5):319.
    2019-02 A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC) Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 319.
    2019-02 Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2 Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 8.
    2019-02 A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number TPS468.
    2019-02 Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 269.
    2018-12 FOXO3a-driven alternation of metabolism dictates the gemcitabine sensitivity Cancer Science. 2018 Dec;109(Suppl. 2):871.
    2018-12 c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation Cancer Science. 2018 Dec;109(Suppl. 2):866.
    2018-12 The epidemiology of gastric cancer in the era of H. pylori eradication: A nation-wide registry-based study in Taiwan Cancer Science. 2018 Dec;109(Suppl. 2):1437.
    2018-11 Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 200P.
    2018-11 M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 153O.
    2018-11 TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer Annals of Oncology. 2018 Nov;29(Suppl. 9):50.
    2018-10 NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P.
    2018-10 The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P.
    2018-10 Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1 Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251.
    2018-10 M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P.
    2018-10 Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P.
    2018-10 Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD.
    2018-09 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286.

    显示项目1-50 / 179. (共4页)
    1 2 3 4 > >>
    每页显示[10|25|50]项目

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈